Study #2021-0168
A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4-CAR-T) in Subjects with Relapsed or Refractory T-Cell Lymphoma (TCL)
MD Anderson Study Status
Not Accepting
Treatment Agent
LB1901
Description
This is a Phase 1, first-in-human (FIH), open-label, multicenter, study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise specified [PTCL-NOS] and angioimmunoblastic [AITL]), or relapsed or refractory cutaneous T-cell lymphoma (CTCL) (Sézary syndrome [SS] and mycosis fungoides [MF]).
Information and next steps
Disease:
T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Recurrent, Peripheral T-Cell Lymphoma Recurrent
Study phase:
I
Physician name:
Swaminathan Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.